86 related articles for article (PubMed ID: 25312543)
1. Liposomal carfilzomib nanoparticles effectively target multiple myeloma cells and demonstrate enhanced efficacy in vivo.
Ashley JD; Stefanick JF; Schroeder VA; Suckow MA; Alves NJ; Suzuki R; Kikuchi S; Hideshima T; Anderson KC; Kiziltepe T; Bilgicer B
J Control Release; 2014 Dec; 196():113-21. PubMed ID: 25312543
[TBL] [Abstract][Full Text] [Related]
2. In vivo evaluation of CD38 and CD138 as targets for nanoparticle-based drug delivery in multiple myeloma.
Omstead DT; Mejia F; Sjoerdsma J; Kim B; Shin J; Khan S; Wu J; Kiziltepe T; Littlepage LE; Bilgicer B
J Hematol Oncol; 2020 Nov; 13(1):145. PubMed ID: 33138841
[TBL] [Abstract][Full Text] [Related]
3. Carfilzomib-Loaded Ternary Polypeptide Nanoparticles Stabilized by Polycationic Complexation.
Agbana P; Park JE; Rychahou P; Kim KB; Bae Y
J Pharm Sci; 2024 Mar; 113(3):711-717. PubMed ID: 37673172
[TBL] [Abstract][Full Text] [Related]
4. Antibody-Mediated Nanodrug of Proteasome Inhibitor Carfilzomib Boosts the Treatment of Multiple Myeloma.
Chen R; Yang J; Mao Y; Zhao X; Cheng R; Deng C; Zhong Z
Biomacromolecules; 2023 Nov; 24(11):5371-5380. PubMed ID: 37801632
[TBL] [Abstract][Full Text] [Related]
5. Identification of
Zhao J; Yang X; Zhang H; Gu X
Oncol Res; 2023; 32(2):325-337. PubMed ID: 38186567
[TBL] [Abstract][Full Text] [Related]
6. Acute suppression of translation by hyperthermia enhances anti-myeloma activity of carfilzomib.
Maruhashi T; Miki H; Sogabe K; Oda A; Sumitani R; Oura M; Takahashi M; Harada T; Fujii S; Nakamura S; Kurahashi K; Endo I; Abe M
Int J Hematol; 2024 Mar; 119(3):291-302. PubMed ID: 38252236
[TBL] [Abstract][Full Text] [Related]
7. Overcoming Solubility Challenges: Liposomal isoCoQ-Carbazole as a Promising Anti-Tumor Agent for Inoperable and Radiation-Insensitive cancers.
Lamaa D; Cailleau C; Vergnaud J; Mougin J; Bignon J; Alami M; Fattal E; Hamze A; Tsapis N
Chembiochem; 2024 May; 25(10):e202400062. PubMed ID: 38536125
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms and Potential Treatment Options of Heart Failure in Patients With Multiple Myeloma.
Proskuriakova E; Jada K; Kakieu Djossi S; Khedr A; Neupane B; Mostafa JA
Cureus; 2021 Jun; 13(6):e15943. PubMed ID: 34336442
[TBL] [Abstract][Full Text] [Related]
9. Dual Carfilzomib and Doxorubicin-Loaded Liposomal Nanoparticles for Synergistic Efficacy in Multiple Myeloma.
Ashley JD; Quinlan CJ; Schroeder VA; Suckow MA; Pizzuti VJ; Kiziltepe T; Bilgicer B
Mol Cancer Ther; 2016 Jul; 15(7):1452-9. PubMed ID: 27196779
[TBL] [Abstract][Full Text] [Related]
10. Current treatment landscape for relapsed and/or refractory multiple myeloma.
Dimopoulos MA; Richardson PG; Moreau P; Anderson KC
Nat Rev Clin Oncol; 2015 Jan; 12(1):42-54. PubMed ID: 25421279
[TBL] [Abstract][Full Text] [Related]
11. Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients.
Blimark C; Holmberg E; Mellqvist UH; Landgren O; Björkholm M; Hultcrantz M; Kjellander C; Turesson I; Kristinsson SY
Haematologica; 2015 Jan; 100(1):107-13. PubMed ID: 25344526
[TBL] [Abstract][Full Text] [Related]
12. Evolving treatments in multiple myeloma patients with renal failure.
Gozzetti A; Papini G; Candi V; Bocchia M
Rev Recent Clin Trials; 2014; 9(4):276-9. PubMed ID: 25329484
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy-induced peripheral neuropathies in hematological malignancies.
Jongen JL; Broijl A; Sonneveld P
J Neurooncol; 2015 Jan; 121(2):229-37. PubMed ID: 25326770
[TBL] [Abstract][Full Text] [Related]
14. Cancer-selective targeting of the NF-κB survival pathway with GADD45β/MKK7 inhibitors.
Tornatore L; Sandomenico A; Raimondo D; Low C; Rocci A; Tralau-Stewart C; Capece D; D'Andrea D; Bua M; Boyle E; van Duin M; Zoppoli P; Jaxa-Chamiec A; Thotakura AK; Dyson J; Walker BA; Leonardi A; Chambery A; Driessen C; Sonneveld P; Morgan G; Palumbo A; Tramontano A; Rahemtulla A; Ruvo M; Franzoso G
Cancer Cell; 2014 Oct; 26(4):495-508. PubMed ID: 25314077
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of Nek2 by small molecules affects proteasome activity.
Meng L; Carpenter K; Mollard A; Vankayalapati H; Warner SL; Sharma S; Tricot G; Zhan F; Bearss DJ
Biomed Res Int; 2014; 2014():273180. PubMed ID: 25313354
[TBL] [Abstract][Full Text] [Related]
16. Novel agents and new therapeutic approaches for treatment of multiple myeloma.
Ria R; Reale A; Vacca A
World J Methodol; 2014 Jun; 4(2):73-90. PubMed ID: 25332907
[TBL] [Abstract][Full Text] [Related]
17. Improved response rates with bortezomib in relapsed or refractory multiple myeloma: an observational study in Chinese patients.
Lin M; Hou J; Chen W; Huang X; Liu Z; Zhou Y; Li Y; Zhao T; Wang L; Wu KW; Shen Z
Adv Ther; 2014 Oct; 31(10):1082-94. PubMed ID: 25331616
[TBL] [Abstract][Full Text] [Related]
18. Phase 1 dose-escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma.
Assouline SE; Chang J; Cheson BD; Rifkin R; Hamburg S; Reyes R; Hui AM; Yu J; Gupta N; Di Bacco A; Shou Y; Martin P
Blood Cancer J; 2014 Oct; 4(10):e251. PubMed ID: 25325301
[TBL] [Abstract][Full Text] [Related]
19. Identification of proteins found to be significantly altered when comparing the serum proteome from Multiple Myeloma patients with varying degrees of bone disease.
Dowling P; Hayes C; Ting KR; Hameed A; Meiller J; Mitsiades C; Anderson KC; Clynes M; Clarke C; Richardson P; O'Gorman P
BMC Genomics; 2014 Oct; 15(1):904. PubMed ID: 25322877
[TBL] [Abstract][Full Text] [Related]
20. Ipilimumab administration for advanced melanoma in patients with pre-existing Hepatitis B or C infection: a multicenter, retrospective case series.
Ravi S; Spencer K; Ruisi M; Ibrahim N; Luke JJ; Thompson JA; Shirai K; Lawson D; Bartell H; Kudchadkar R; Gunter NT; Mehnert JM; Lipson EJ
J Immunother Cancer; 2014; 2(1):33. PubMed ID: 25317333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
